Cerebral venous thrombosis after COVID-19 vaccination: is the risk of thrombosis increased by intravascular application of the vaccine?

Lutz Gürtler1 · Rainer Seitz2 · Wolfgang Schramm3

Received: 25 May 2021 / Accepted: 30 June 2021 / Published online: 21 July 2021
© The Author(s) 2021

Keywords Venous thrombosis · SARS-CoV-2 vaccination · Adenovirus vector · PF4 antibody · Thrombocytopenia

Currently, an unprecedented campaign of vaccination against COVID-19 is carried out worldwide, involving many millions of people. Pre-licensing clinical studies of new vaccines can include only a limited number of subjects; therefore rigorous pharmacovigilance is warranted to detect rare side effects.

The surveillance of the recombinant adenovirus-based COVID-19 vaccine ChAdOx1-S (Oxford, Astra-Zeneca) which contains chimpanzee adenovirus (AdV) encoding the SARS-CoV-2 spike glycoprotein, revealed rare thromboses with concurrent thrombocytopenia, including venous thromboses in unusual sites such as cerebral venous sinus thrombosis (CVST), intestinal venous and arterial thromboses [1]. Soon thereafter, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) reported also a signal concerning thromboembolic events with thrombocytopenia after vaccination with the Ad26.COV2-S COVID-19 vaccine (Johnson & Jonhson) [2], which contains the cloned SARS-CoV-2 spike glycoprotein in AdV type 26. Both above-mentioned vaccines are abbreviated in the following as AdV-S. The above described thrombotic complications after AdV-S have in the meantime be named TTS (thrombosis thrombocytopenia syndrome), VIPIT (vaccine-induced prothrombotic immune thrombocytopenia) or VITT (vaccine-induced thrombocytopenia) [3–5].

For other SARS-CoV-2 vaccines, which do not use adenovirus vectors, similar observations were only reported until now in two women [6, 7].

Most of the cases reported to date have occurred in persons under 60 years of age within 2 weeks of receiving the first vaccine dose [3]. Since females consented more frequently to be vaccinated there were more female than male vaccinees involved, but this observation is in line with the experience concerning risk factors for cerebral venous sinus thrombosis [8–11]. The occurrence of thrombosis focused on CVST after AdV-S vaccination, and has to be balanced with the frequency of spontaneous cerebral venous sinus thrombosis [12], and CVST associated with SARS-CoV-2 infection [13, 14]. The time period of the occurrence of CVST in COVID-19 patients even under anti-thrombotic treatment is reported to be ca 3–30 days after onset of infection [3, 15]. It was reported that in patients with COVID-19 pneumonia an incidence between 7.7 and 28% of cerebral thrombosis was found in Intensive Care Units, dependent on age, gender, comorbidities, and cytokine release, compared to a general incidence of 2–5–15 cases per million people [9]. The frequency of atypical thrombosis after vaccination has to be weighted with that of thrombosis in the general population [16], and the higher frequency of thrombosis in COVID-19 patients in emergency departments, which will be strongly reduced by vaccination [17, 18]. Factors contributing to the preferential affection of female gender in the observed thromboses after AdV-S vaccination may include increased seasonal adenovirus production supported by beta-estradiol [19] and hormonal activation of thrombocytes [20]. There may be further some contribution to a tendency of hypercoagulation by genetic factors, since the...
Innate immunological response to the vector, characterized by rapid increases in levels of serum cytokines and chemokines, and subsequent adaptive immunological responses that restrict repeated administration of the vector. Moreover, intravascular application of AdV-based vaccines is limited by the inherent hepatic tropism of some AdV and by the associated host inflammatory responses to the vector [31, 32], as well as interaction with platelets [33], endothelial cells, and coagulation cascade [26, 34]. Thus, AdV-S vaccine invading the bloodstream may directly contribute to thrombocyte activation [5]. PEGylation of AdV5 used as a vector for gene therapy reduced the toxicity, clotting and complement activation, cytokine release in human blood, while iv application of the AdV-S might be associated with cytokine storm, hypercoagulation and liver cell necrosis [35]. Factor X (FX) binds to the hexon of AdV5 and promotes entry to hepatocytes, and activation of the TRL4 related pathway [34].

To reduce side effects the present AdV-S vaccine is based on AdV encoding the S1 glycoprotein of SARS-CoV-2 corresponding to $2.5 \times 10^8$ infectious units (IU) (manufacturer’s information). The vaccine has to be injected IMtransmuscularly and the cloned AdV will attach to myocytes, fibroblasts, dendritic cells, macrophages and further cells near the injection site as antigen-presenting cells [29]. The cloned virus induces a strong immune response [36] especially after the second boost injection of the vaccine with a broad T-cell immune response and production of IgG antibodies [37] that are distributed by the lymphogenic and haematogenic route. In blood AdV will attach to all cells, including erythrocytes [38] and platelets, heparan, heparan sulfate, glycosaminoglycan [29], and activate platelets [34], form complexes, that might attach to endothelial cells and induce cytokine release [5, 31]. A further way of complex formation is the liberation of AdV-DNA by antigen-presenting cells, by microtrauma or microbleeding resulting in intravascular access and attachment of AdV-DNA to PF4 and finally leading to VITT [5]. DNA shares electrochemical similarities with heparin, binds to PF4, and complexes with PF4 autoantibodies which are found more frequently in younger females [5]. When these complexes circulate in the bloodstream they might be dispersed during their passage through capillaries or might grow in sites prone for turbulences and shearing forces as for example in the carotid sinus [39] attach to the endothelium and finally cause CVST [14, 25].

According to current recommendations [40], aspiration before IM intramuscular injection of vaccines or toxoids (i.e., pulling back on the syringe plunger after IM intramuscular needle insertion, but before injection) is no longer necessary because no large blood vessels are present at the recommended deltoid muscle injection site. If by chance the vaccine is injected into a blood vessel, the AdV-S will attach to blood cells and endothelial cells, and activate thrombocytes. After 1–2 weeks activated thrombocytes might lead to the formation of complexes of blood cells, in the presence of PF4 antibodies and components of the clotting system and possibly lead to thrombosis [3, 5, 25]. Regarding the kinetics and time and frequency of thrombosis formation after vaccination, there is room for speculation that clot formation would be fostered by intravascular application of the vaccine, which still is a rare event of < 1 in 100,000 [5]. Whether a technical reason- no aspiration, injection at the wrong site-, or anatomical reason aberrant large vessels, presence of haemangioma-, or immunological reason e.g. hyperreactivity of thrombocytes contribute to the pathological reaction to AdV-S vaccine application gives room for
further investigation in vaccine application, especially on the technical site.

The overall risk–benefit balance in favour of vaccination remains clearly positive [37]. However, according to the bad experiences with the initial intravascular AdV vector-based gene therapy, adverse effects by the intravascular application of AdV-S vaccine should be avoided, and a strictly IM intramuscular injection should be warranted.

Author contributions All authors contributed equally to the completion of the manuscript.

Declarations

Conflict of interest All authors have no conflict of interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Hernández AF, Calina D, Poulas K, Docea AO, Tsatsakis AM. Safety of COVID-19 vaccines administered in the EU: should we be concerned? Toxicol Rep 2021;8:871–79.
2. Vallée A, Chan-Hew-Wai A, Bonan B, Lesprit P, Parquin F, Catherinot E et al. Oxford-AstraZeneca COVID-19 vaccine: need of a reasoned and effective vaccine campaign. Public Health 2021;196:135–37.
3. Long B, Bridwell R, Gottlieb M. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines. Am J Emerg Med. 2021;49:58–61.
4. Thater J, Ay C, Gleixner KV, Hauswirth AW, Cacioppo F, Grafeneder J, et al. Successful treatment of vaccine induced pro-thrombotic immune thrombocytopenia (VITIP). J Throm Haemost. 2021;19:191819–22.
5. McGonagle D, De Marco G, Bridgewood C. Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection. J Autoimmunity. 2021;1:12102662.
6. Al Maqbal JS, Al Maqbal S, Kashouh MS, Al Hinaai AM, Farhan H, Rawahi A, et al. A 59-year-old women with extensive deep vein thrombosis and pulmonary thromboembolism 7 days following a first dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine. Am J Case Rep. 2021;22: e932946.
7. De Bruijn S, Maes MB, De Waele L, Vanhoorelbeke K, Gadsseur A. First report of a de novo ITPP episode associated with an mRNA-based anti-COVID-19 vaccination. J Thromb Haemost. 2021. https://doi.org/10.1111/JTH.15418.
8. Capecci M, Abbattista M, Martinelli I. Cerebral venous sinus thrombosis. J Thrombos Haemost. 2018;16:1918–31.
9. Dakay K, Cooper J, Bloomfield J, Overby P, Mayer SA, Nuoman R, et al. Cerebral venous thrombosis as a presentation of COVID-19. J Stroke Cerebrovascular Dis. 2021;30:105434.
10. Furlan M, Robles R, Galbuseera M, Remuzzi G, Kyle PA, Brenner B, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N Engl J Med. 1998;339:1578–84.
11. RIKI. Beschluss der STIKO zur 4. Aktualisierung der COVID-19 Impfung und die dazugehörige wissenschaftliche Begründung. Epidemiol Bull. 2021;16:1–8.
12. Dentali F, Gianni M, Crowther MA, Ageno W. Natural history of cerebral vein thrombosis: a systematic review. Blood. 2006;108:1129–34.
13. Violi F, Pastori D, Cangioli R, Pignatelli P, Loffredo L. Hypercoagulation and anti-thrombotic treatment in coronavirus 2019. Thromb Haemost. 2020;120:949–56.
14. Snell J. SARS-CoV-2 infection and its association with thrombosis and ischemic stroke: a review. Am J Emerg Med. 2021;40:188–92.
15. Friedrich SM, Stutd JD, Braun J, Spahn DR, Kaserer A. Coronavirus induced coagulopathy during the course of disease. PLoS ONE. 2020;15: e0243409.
16. Østergaard SD, Schmidt M, Horváth-Puhó E, Thomsen RW, Sörensen HAT. Thromboembolism and the Oxford-Astra Zeneca COVID-19 vaccine: side-effect or coincidence. Lanet. 2021;397:1441–3.
17. Rieder M, Goller I, Jeseric M, Baldus N, Pollmeier L, Wirth L, et al. Rate of venous thromboembolism in a prospective all-comes cohort with COVID-19. J Thromb Thrombolysis. 2020;50:558–66.
18. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46:1089–98.
19. James CBL, Vanderpool EA, Roane P. Acceleration of adenovirus replication and increased virion production by treatment with the steroid hormone 17 beta-estradiol. Microbiol Immunol. 1992;36:99–103.
20. Farré AL, Modrego J, Zamorano-León JJ. Effects of hormones on platelet aggregation. Hom Mol Biol Clin Invest. 2014;18:27–36.
21. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Manucci PM. High risk of cerebral vein thrombosis in carriers of a prothrombin gene mutation and in users of oral contraceptives. N Engl J Med. 1998;338:1793–7.
22. González JV, Barboza AG, Vazquez FJ, Gandara E. Prevalence and geographic variation of prothrombin G20210A mutation in patients with cerebral vein thrombosis: a systematic review and meta-analysis. PLoS ONE. 2016;11: e0151607.
23. Manucci PM. Thrombotic microangiopathies: the past as prologue. Eur J Int Med. 2013;24:484–5.
24. Greinacher A, Thiele T, Warkentin TE, Weissier K, Kyrl P, Eichinger S. A thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination. New Eng J Med. 2021. https://doi.org/10.1056/NEJMoa2104840.
25. Schulitz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. New Eng J Med. 2021;384:2124–30. https://doi.org/10.1056/NEJMoa2104882.
26. Cai Z, Greene MI, Zhu Z, Zhang H. Structural features and PF4 functions that occur in heparin-induced thrombocytopenia (HIT) complicated by COVID-19. Antibodies (Basel). 2020:9:52.
27. Volkmann ER, Taskhin DP, Roth MD, Clements PJ, Khanna D, Furst DE, et al. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving
immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. Arthritis Res Ther. 2016;18:305.
28. Nazy I, Staibano CP, Warkentin TE, Larche M, Moore JC, Smith JW, et al. Cellular immune response to platelet factor 4 and heparin complexes in patients with heparin-induced thrombocytopenia. J Thromb Haemost. 2018;16:1402–12.
29. Dechecchi MC, Tamanini A, Bonizzato A, Cabrini G. Heparan sulfate glycosaminoglycans are involved in adenovirus Type 5 and 2-host cell interactions. Virology. 2000;268:382–90.
30. Greinacher A. Heparin-induced thrombocytopenia. J Thromb Haemost. 2009;7(Suppl. 1):9–12.
31. Parker AL, Nicklin SA, Baker AH. Interactions of adenovirus vectors with blood: Implications for intravascular gene therapy applications. Curr Opin Mol Ther. 2008;10:1–20.
32. Bary M. Single cycle adenovirus vectors in the current vaccine landscape. Expert Rev Vaccines. 2018;17:163–73.
33. Stone D, Liu Y, Shayakhmetov D, Li Z-Y, Ni S, Lieber A. Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J Virology. 2007;81:4866–71.
34. Antoniak S, Mackman N. Multiple roles of the coagulation protease cascade during virus infection. Blood. 2014;123:2605–13.
35. Danielsson A, Elgue G, Nilsson BM, Nilsson B, Lambris JD, Tönttermann TH, et al. An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood. Gene Ther. 2010;17:752–62.
36. Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim results of a phase 1–2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2034201.
37. Angeli F, Spanevello A, Reboldi G, Visca D, Verdeccchia P. SARS-CoV-2 vaccines: lights and shadows. Eur J Int Med. 2021;88:1–8.
38. Schagen FHE, Graat CA, Carette JE, Vellinga J, van Geer MA, Hoeben RC, et al. Replacement of native adenovirus receptor binding sites with a new attachment moiety diminishes hepatic tropism and enhances bioavailability in mice. Hum Gene Ther. 2008;19:783–94.
39. Lehmann M, Schoeman RM, Krohl PI, Wallbank AM, Samaniuk JR, Perrus MJ, Neeves KB. Platelets drive thrombus propagation in a hematocrit and glycoprotein VI-dependent manner in an in vitro venous thrombosis model. Aterioscler Thromb Vas Biol. 2018;38:1052–62.
40. Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). 2021. www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf